Barclays PLC Boosts Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Barclays PLC raised its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 17.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 474,953 shares of the medical equipment provider's stock after buying an additional 69,480 shares during the period. Barclays PLC owned approximately 0.24% of Zimmer Biomet worth $50,171,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ZBH. Roman Butler Fullerton & Co. purchased a new position in Zimmer Biomet in the fourth quarter valued at $473,000. KLCM Advisors Inc. purchased a new position in shares of Zimmer Biomet in the 4th quarter valued at about $7,825,000. Peddock Capital Advisors LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter worth about $654,000. Van ECK Associates Corp increased its stake in shares of Zimmer Biomet by 5.9% during the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after buying an additional 218,688 shares during the period. Finally, Reinhart Partners LLC. increased its stake in shares of Zimmer Biomet by 34.4% during the fourth quarter. Reinhart Partners LLC. now owns 86,755 shares of the medical equipment provider's stock worth $9,164,000 after buying an additional 22,220 shares during the period. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Price Performance

Shares of ZBH traded up $3.36 during mid-day trading on Wednesday, reaching $100.80. 405,169 shares of the company's stock were exchanged, compared to its average volume of 1,652,888. Zimmer Biomet Holdings, Inc. has a 52-week low of $93.10 and a 52-week high of $123.96. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company has a 50-day simple moving average of $105.82 and a two-hundred day simple moving average of $106.62. The company has a market cap of $19.94 billion, a price-to-earnings ratio of 22.65, a PEG ratio of 1.95 and a beta of 0.84.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the company earned $2.20 EPS. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's dividend payout ratio is presently 21.57%.

Analysts Set New Price Targets

Several research analysts have commented on ZBH shares. JMP Securities reiterated a "market outperform" rating and set a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Stifel Nicolaus upped their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a research report on Thursday, January 23rd. Royal Bank of Canada cut their target price on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Finally, Barclays reduced their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $124.15.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.70% of the company's stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.